THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and UCB announced the submission of a
Biologics License Application (BLA) to the U.S. Food and Drug Administration for
romosozumab, an investigational monoclonal antibody for the treatment of
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and UCB announced that the BRIDGE
study met the primary endpoint, demonstrating a statistically significant
increase in bone mineral density at the lumbar spine in men with osteoporosis
UCB has terminated its nearly 10-year-old collaboration with Immunomedics to develop and commercialize the latter’s lead candidate epratuzumab for all non-cancer indications worldwide. No reason for the termination was disclosed by Immunomedics...
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and UCB announced top-line results
from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with
ostEoporosis or FRAME. These data showed FRAME met the co-primary endpoints by
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):